Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Swiss National Bank

Key Points

• Swiss National Bank reduced its holdings in Regeneron Pharmaceuticals by 0.5%, owning 304,800 shares worth approximately $193.31 million as of the end of the most recent quarter.
• Several institutional investors significantly increased their stakes in Regeneron, with GAMMA Investing LLC raising holdings by 89,825% and Capital International Investors increasing by 41.6%.
• Regeneron reported earnings of $12.89 per share for the last quarter, surpassing analysts' expectations, and announced a quarterly dividend of $0.88 per share, reflecting a yield of 0.6%.

Swiss National Bank lowered its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 0.5% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 304,800 shares of the biopharmaceutical company's stock after selling 1,500 shares during the quarter. Swiss National Bank owned about 0.28% of Regeneron Pharmaceuticals worth $193,313,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Adirondack Trust Co. grew its stake in Regeneron Pharmaceuticals by 4.2% during the 1st quarter. Adirondack Trust Co. now owns 451 shares of the biopharmaceutical company's stock valued at $286,000 after purchasing an additional 18 shares in the last quarter. Kingswood Wealth Advisors LLC grew its stake in Regeneron Pharmaceuticals by 1.8% during the 1st quarter. Kingswood Wealth Advisors LLC now owns 1,084 shares of the biopharmaceutical company's stock valued at $681,000 after purchasing an additional 19 shares in the last quarter. Creative Financial Designs Inc. ADV grew its stake in Regeneron Pharmaceuticals by 9.5% during the 1st quarter. Creative Financial Designs Inc. ADV now owns 220 shares of the biopharmaceutical company's stock valued at $139,000 after purchasing an additional 19 shares in the last quarter. Private Trust Co. NA grew its stake in Regeneron Pharmaceuticals by 13.1% during the 1st quarter. Private Trust Co. NA now owns 164 shares of the biopharmaceutical company's stock valued at $104,000 after purchasing an additional 19 shares in the last quarter. Finally, Proficio Capital Partners LLC grew its stake in Regeneron Pharmaceuticals by 6.2% during the 1st quarter. Proficio Capital Partners LLC now owns 327 shares of the biopharmaceutical company's stock valued at $207,000 after purchasing an additional 19 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Wall Street Analysts Forecast Growth

REGN has been the subject of several research reports. Bank of America decreased their target price on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a research report on Thursday, April 17th. JPMorgan Chase & Co. decreased their target price on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating for the company in a research report on Monday, June 9th. Argus lowered Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Monday, June 30th. Wall Street Zen lowered Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 1st. Finally, Cantor Fitzgerald assumed coverage on Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 target price for the company. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $841.30.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock traded up $3.20 during mid-day trading on Friday, hitting $563.00. 1,024,297 shares of the stock traded hands, compared to its average volume of 978,475. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $1,211.20. The firm has a market cap of $59.67 billion, a price-to-earnings ratio of 14.19, a price-to-earnings-growth ratio of 1.91 and a beta of 0.33. The company's 50-day simple moving average is $536.80 and its 200-day simple moving average is $598.52. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%. The company had revenue of $3,675,600 billion for the quarter, compared to analysts' expectations of $3.30 billion. During the same period last year, the firm earned $11.56 EPS. The firm's revenue for the quarter was up 3.6% on a year-over-year basis. As a group, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th will be given a dividend of $0.88 per share. The ex-dividend date is Monday, August 18th. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.